The Journal of Practical Medicine ›› 2022, Vol. 38 ›› Issue (6): 673-677.doi: 10.3969/j.issn.1006⁃5725.2022.06.005

• Review • Previous Articles     Next Articles

Progress of tuberculosis subunit vaccine in clinical research

DU Jingjin∗#，PANG Yu，LI Ling.   

  1. School of Basic Medical Science，Guangdong Medical University，Dongguan 523000，China；#Department of Bacteriology and Immunology，Beijing Chest Hospital，Capital Medical University，Beijing Tuberculosis and Thoracic Tumor Research Institute，Beijing 101149，China 

  • Online:2022-03-25 Published:2022-03-25
  • Contact: PANG Yu E⁃mail：pangyupound@163.com；LI Ling E⁃mail：liling@smu.edu.cn

Abstract:

Tuberculosis is still the main infectious disease that causes adult deaths worldwide and has been a global public health challenge for the past 25 years. At present，the only approved tuberculosis vaccine is BCG and there is still a long way to go to develop safer and more effective vaccine of tuberculosis. Recombinant subunit vaccines have clear components，high safety，can induce high⁃efficiency immune responses，and provide long⁃term immune protection effects. So they have good application prospects. This article reviewed the progress in the components，clinical research status，and application of the tuberculosis recombinant subunit vaccine.

Key words:

tuberculosis（TB）, Mycobacterium tuberculosis（M.tb）, subunit vaccine, antigen, adjuvant